粪菌移植治疗女性复发性尿路感染:非抗菌策略的定位探讨
该叙述性综述总结了粪菌移植(FMT)治疗女性复发性尿路感染(rUTI)的现有证据,排除存在机械性功能障碍者,并与其他非抗菌干预比较。综述指出,肠道与阴道菌群定植及病原体迁移与女性UTI病因相关,FMT在预防rUTI临床发作方面似乎有前景,但前瞻性数据仍有限;其他针对肠道与泌尿生殖道菌群的非抗菌策略疗效不一。需前瞻性随机对照试验进一步确认疗效、优化FMT流程并评估成本效益。
要点
- FMT预防女性rUTI的临床证据仍有限,需前瞻性随机对照试验确认。
- 肠道与阴道菌群病原体定植及迁移与女性UTI病因相关。
- 其他靶向菌群的非抗菌策略临床疗效报道不一。
核心结论
- FMT似乎是预防女性rUTI临床发作的有前景方法,但前瞻性数据仍有限。
- 需前瞻性随机对照试验进一步确认FMT的潜在治疗获益、优化操作流程并评估成本效益。
研究设计与样本
- 叙述性综述,聚焦女性rUTI患者,排除尿失禁、神经源性膀胱和膀胱癌等机械性功能障碍者。
- 比较FMT与其他非抗菌干预,并讨论rUTI的病理生理与流行病学以识别可能最适合菌群靶向治疗的患者。
主要发现
- 约三分之一女性在首次UTI后发生rUTI。
- 肠道和阴道定植的尿路病原体围绕尿道定植并迁移至膀胱,与女性UTI病因相关,尤其在多重耐药菌感染者中。
- FMT在预防rUTI临床发作方面似乎有前景,但前瞻性数据仍有限。
- 其他靶向肠道和泌尿生殖道菌群的非抗菌策略显示出不一但显著的临床疗效。
临床怎么用
- 对于反复发作rUTI的女性,可关注菌群靶向治疗(包括FMT)的潜在价值,但目前应限于研究或严格评估场景。
- 选择菌群靶向治疗对象时,可考虑存在肠道/阴道尿路病原体定植尤其多重耐药菌感染者。
- 排除机械性功能障碍(如尿失禁、神经源性膀胱、膀胱癌)患者后再评估FMT适用性。
局限性
- 为叙述性综述,FMT相关前瞻性数据仍有限。
- 其他非抗菌策略的临床疗效报道不一。
- FMT操作流程尚未优化,成本效益有待评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent urinary tract infection (rUTI) is a common condition, affecting approximately one-third of women after an initial UTI. It significantly impacts health care costs and patients' quality of life. The relationship between the pathophysiology of UTI and the gut and vaginal microbiota is recognized as a contributing factor to rUTI in women. As antibiotic resistance among uropathogens continues to increase, there is a clear need to develop novel therapeutic interventions. Faecal microbiota transfer (FMT) is a potent nonantimicrobial strategy for modulating the gut microbiota; however, its clinical relevance in the context of rUTI is unclear. OBJECTIVES: This narrative review aimed to summarize the current evidence on the use of FMT for the treatment of rUTI, focusing on women, excluding those with mechanical dysfunctions such as urinary incontinence, neurogenic bladder, and bladder cancer, compared with other nonantimicrobial interventions. We also discussed the pathophysiology and epidemiology of rUTI to identify patients for whom microbiota-targeting therapies may be the most effective. CONTENT: Periurethral colonization and migration to the bladder of uropathogens that inhabit the gut and vagina have been linked to the aetiology of UTI in women, particularly in patients with multidrug-resistant organisms. FMT appears to be a promising approach for preventing the clinical development of rUTI, although prospective data remain limited. In contrast, other reported nonantimicrobial strategies targeting the gut and urogenital microbiota have shown variable significant clinical efficacy. Prospective randomized controlled clinical trials are then needed to further confirm a potential therapeutic benefit, optimize the FMT procedure, and better assess its cost-effectiveness.
引用
- Cassir N, Ghani R, Biehl LM, et al. Nonantimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer? Clin Microbiol Infect. 2025. PMID: 40744276. doi:10.1016/j.cmi.2025.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。